GnRH‐a + raloxifene vs GnRH‐a ± placeboQoL · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 74 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboUterine size (cm3) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboUterine bleeding · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboSeverity of vasomotor symptoms · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboRate of vasomotor symptoms ‐ · patients with uterine fibroidsThe review found no eligible studies for this question.1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found